Literature DB >> 11279344

Laser microdissection and microsatellite analyses of breast cancer reveal a high degree of tumor heterogeneity.

P Wild1, R Knuechel, W Dietmaier, F Hofstaedter, A Hartmann.   

Abstract

Carcinomas with productive fibrosis are the most common forms of breast cancer. Analysis of tumor-specific genomic alterations can be compromised by the presence of normal cells, demanding microdissection of small tumor areas to detect loss of heterozygosity (LOH) and microsatellite instability (MSI). The aim of this study was to evaluate the importance of precise laser microdissection for microsatellite analyses and investigation of tumor heterogeneity in breast cancer. 39 primary breast tumor samples were analyzed for MSI and LOH by PCR followed by polyacrylamide gel electrophoresis and silver staining using 15 microsatellite markers. Different tumor areas were processed separately in 30 patients. Both intraductal and invasive breast cancer regions were investigated in 11 patients. The following results were obtained: (1) accurate microdissection revealed MSI in 3 or more of the investigated markers (> or =20%) in 33% of the patients, a higher frequency than reported previously; (2) laser microdissection was 43% more sensitive in detection of LOH compared to manual microdissection due to a reduction of contamination by normal cells, and (3) 29 of 30 investigated tumors showed heterogeneity of genetic alterations in different tumor regions. Laser-based microdissection is a valuable tool in genetic analysis of desmoplastic tumors and allows an accurate determination of genetic alterations in histologically different tumor regions. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2000        PMID: 11279344     DOI: 10.1159/000055921

Source DB:  PubMed          Journal:  Pathobiology        ISSN: 1015-2008            Impact factor:   4.342


  7 in total

1.  Premalignant lesions of the kidney share the same genetics changes as conventional renal cell carcinoma.

Authors:  S Pehlivan; M Koyuncuoglu; M Pehlivan; S Izzetoglu; Y Mater; M Cabuk; Z Kirkali
Journal:  World J Urol       Date:  2003-12-20       Impact factor: 4.226

Review 2.  Moonshot Objectives: Catalyze New Scientific Breakthroughs-Proteogenomics.

Authors:  Karin D Rodland; Paul Piehowski; Richard D Smith
Journal:  Cancer J       Date:  2018 May/Jun       Impact factor: 3.360

3.  Putative precursor cancer cells in human colorectal cancer tissue.

Authors:  Teodora E Goranova; Masayuki Ohue; Kikuya Kato
Journal:  Int J Clin Exp Pathol       Date:  2008-07-14

4.  Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer.

Authors:  F Bataille; P Rümmele; W Dietmaier; D Gaag; F Klebl; A Reichle; P Wild; F Hofstädter; A Hartmann
Journal:  Mol Pathol       Date:  2003-10

5.  Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo.

Authors:  Huan Meng; Wilson X Mai; Haiyuan Zhang; Min Xue; Tian Xia; Sijie Lin; Xiang Wang; Yang Zhao; Zhaoxia Ji; Jeffrey I Zink; Andre E Nel
Journal:  ACS Nano       Date:  2013-01-04       Impact factor: 15.881

6.  Mechanisms and insights into drug resistance in cancer.

Authors:  Hiba Zahreddine; Katherine L B Borden
Journal:  Front Pharmacol       Date:  2013-03-14       Impact factor: 5.810

Review 7.  Expression profiling of small cellular samples in cancer: less is more.

Authors:  J G Glanzer; J H Eberwine
Journal:  Br J Cancer       Date:  2004-03-22       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.